Skip to main content

Halstead Michael's Form 4 filing

Intra-Cellular Therapies, Inc. (ITCI) · filed Nov 14, 2023

Accession no.
0001209191-23-055207
Filed
Nov 14, 2023
Trade date
Nov 13, 2023
Filing delay
1 day
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.69M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Halstead MichaelCIK 0001521548Officer (EVP and General Counsel)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 13, 2023Common StockMOption exerciseAcquired+15,164$15.47+$234,587.0815,164Direct
Nov 13, 2023Common StockMOption exerciseAcquired+34,836$12.73+$443,462.2850,000Direct
Nov 13, 2023Common StockSSaleDisposed−8,933$53.37−$476,754.2141,067Direct
Nov 13, 2023Common StockSSaleDisposed−41,067$54.01−$2,218,028.670Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 13, 2023Common StockMOption exerciseDisposed−15,164$0.00$00Direct
Nov 13, 2023Common StockMOption exerciseDisposed−34,836$0.00$046,115Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)